RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology.
Last week the Food and Drug Administration released its draft guidance on the interchangeability between biosimilars and originator biologic drugs. (Citation source: http://buff.ly/2k9f79y)
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.
Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.
The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).
In 1998 the biologic era came in like a lion and has been roaring since. The TNF inhibitors have dominated the market from 1999 to present and have been unopposed until the introduction of new target targeted therapies.
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Several important lines of population and large cohort research have shown that rheumatoid arthritis (RA) patients have a substantially higher risk for myocardial infarction and major cardiovascular events.
Dr. Jack Cush reviews highlights from this week on RheumNow.com
Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.
Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
